BACKGROUND: There are emerging reports that the family of a disintegrin and metalloproteinases (ADAM) are involved in the maintenance of the malignant phenotype of glioblastomas. Notably, ADAM proteases 10 and 17 might impair the immune recognition of glioma cells via the activating immunoreceptor NKG2D by cleavage of its ligands from the cell surface. Glioblastoma-initiating cells (GIC) with stem cell properties have been identified as an attractive target for immunotherapy. However, GIC immunogenicity seems to be low. METHODS AND RESULTS: Here,we show that ADAM10 and ADAM17 are expressed on the cell surface of GIC and contribute to an immunosuppressive phenotype by cleavage of ULBP2. The cell surface expression of ULBP2 is enhanced upon blocking ADAM10 and ADAM17, and treatment with ADAM10 and ADAM17specific inhibitors leads to enhanced immunerecognition of GIC by natural killer cells. CONCLUSIONS: Therefore, ADAM10 and ADAM17 constitute suitable targets to boost an immune response against GIC.
BACKGROUND: There are emerging reports that the family of a disintegrin and metalloproteinases (ADAM) are involved in the maintenance of the malignant phenotype of glioblastomas. Notably, ADAM proteases 10 and 17 might impair the immune recognition of glioma cells via the activating immunoreceptor NKG2D by cleavage of its ligands from the cell surface. Glioblastoma-initiating cells (GIC) with stem cell properties have been identified as an attractive target for immunotherapy. However, GIC immunogenicity seems to be low. METHODS AND RESULTS: Here,we show that ADAM10 and ADAM17 are expressed on the cell surface of GIC and contribute to an immunosuppressive phenotype by cleavage of ULBP2. The cell surface expression of ULBP2 is enhanced upon blocking ADAM10 and ADAM17, and treatment with ADAM10 and ADAM17specific inhibitors leads to enhanced immunerecognition of GIC by natural killer cells. CONCLUSIONS: Therefore, ADAM10 and ADAM17 constitute suitable targets to boost an immune response against GIC.
Entities:
Keywords:
NK cell; NKG2D; a disintegrin and metalloproteinase (ADAM); glioblastoma; immunotherapy; stem cell
Authors: Günter Eisele; Jörg Wischhusen; Michel Mittelbronn; Richard Meyermann; Inja Waldhauer; Alexander Steinle; Michael Weller; Manuel A Friese Journal: Brain Date: 2006-08-03 Impact factor: 13.501
Authors: Christian Hundhausen; Dominika Misztela; Theo A Berkhout; Neil Broadway; Paul Saftig; Karina Reiss; Dieter Hartmann; Falk Fahrenholz; Rolf Postina; Vance Matthews; Karl-Josef Kallen; Stefan Rose-John; Andreas Ludwig Journal: Blood Date: 2003-04-24 Impact factor: 22.113
Authors: Manuel A Friese; Michael Platten; Stefan Z Lutz; Ulrike Naumann; Steffen Aulwurm; Felix Bischof; Hans-Jörg Bühring; Johannes Dichgans; Hans-Georg Rammensee; Alexander Steinle; Michael Weller Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: Ana Jimenez-Pascual; James S Hale; Anja Kordowski; Jamie Pugh; Daniel J Silver; Defne Bayik; Gustavo Roversi; Tyler J Alban; Shilpa Rao; Rui Chen; Thomas M McIntyre; Giorgio Colombo; Giulia Taraboletti; Karl O Holmberg; Karin Forsberg-Nilsson; Justin D Lathia; Florian A Siebzehnrubl Journal: Cancer Discov Date: 2019-08-21 Impact factor: 39.397
Authors: Nina Hedemann; Andreas Herz; Jan Hendrik Schiepanski; Jan Dittrich; Susanne Sebens; Astrid Dempfle; Julia Feuerborn; Christoph Rogmans; Nils Tribian; Inken Flörkemeier; Jörg Weimer; Sandra Krüger; Nicolai Maass; Dirk O Bauerschlag Journal: Cancers (Basel) Date: 2021-04-23 Impact factor: 6.639